adult-onset Still’s disease
Conditions
Interventions
Sirolimus combination therapy group:Sirolimus combination therapy
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age over 18 years; 2. Meeting the Yamaguchi criteria, with infection and malignancy excluded; 3. Meeting the definition of refractory AOSD, i.e., patients whose symptoms show no significant improvement after treatment with glucocorticoids at 1 mg/kg, or who experience relapse during tapering of glucocorticoids to 15 mg/d; 4. Complete clinical information; 5. Signed and dated informed consent form; 6. Willingness to comply with study procedures and cooperate throughout the entire study.
Exclusion criteria
Exclusion criteria: 1. Presence of other rheumatic diseases; 2. History of, or planned, hematopoietic stem cell transplantation; 3. Presence of severe comorbidities considered by the investigator to be unsuitable for participation in this clinical study, such as severe cardiac or pulmonary insufficiency, severe bone marrow suppression, or severe hepatic or renal dysfunction; 4. Acute conditions such as bowel perforation or complete intestinal obstruction; 5. Pregnant, planning pregnancy, or breastfeeding women; 6. Poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AOSD Disease Activity Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| AOSD Disease Activity Score;CRP, ESR, serum ferritin, soluble interleukin-2 receptor (sIL-2R), and multiple inflammatory cytokines;Expression level of ZFP36L2 in neutrophils;Clinical symptoms such as rash and arthralgia; | — |
Countries
China
Contacts
Public ContactHonglei Liu
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed